Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Tucatinib

These articles are all highly relevant Tucatinib. I believe this information can help you understand Tucatinib's professional information. If you want to know more, you can contact us at any time, we can provide you with more professional guidance.
  • Drug Patent & Exclusivity Expiration Report - Week of Nov 11 2024

    2024-11-11

    This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's XARELTO, containing active ingredient RIVAROXABAN - KYOWA KIRIN INC's NOURIANZ, containing active ingredient ISTRADEFYLLINE - SEAGEN INC's TUKYSA, containing active ingredient TUCATINIB - VANDA PHARMACEUTICALS INC's PONVORY, containing active ingredient PONESIMOD - AVEO PHARMACEUTICALS INC's FOTIVDA, containing active ingredient TIVOZANIB HYDROCHLORIDE - BIOMARIN PHARMACEUTICAL INC's KUVAN, containing active ingredient SAPROPTERIN DIHYDROCHLORIDE - PROVENSIS LTD's VARITHENA, containing active ingredient POLIDOCANOL - BEIGENE USA INC's BRUKINSA, containing active ingredient ZANUBRUTINIB - SHIONOGI INC's FETROJA, containing active ingredient CEFIDEROCOL SULFATE TOSYLATE Read More